Atea Pharmaceuticals, Inc.

As of February 28, 2023, Atea Pharmaceuticals, Inc. is considered overvalued with significant financial concerns, reflected in its negative P/E ratio, low Price to Book Value, and unfavorable comparison to peers, despite a recent stock performance that outpaced the S&P 500.

As of May 27, 2025, the technical trend is mildly bearish, influenced by daily moving averages and mixed signals from Bollinger Bands, despite some mildly bullish indicators from the weekly MACD and Dow Theory.

As of March 2022, the management team of Atea Pharmaceuticals, Inc. is led by Mr. Jean-Pierre Sommadossi, who is the Chairman of the Board, Chief Executive Officer, and Founder.

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing antiviral therapeutics. As of March 2025, it has a market cap of $274.71 million and reported a net profit loss of $34 million.

As of Jun 18, Atea Pharmaceuticals, Inc. has a market capitalization of 274.71 million and reported net sales of 0.00 million with a net profit of -139.48 million over the latest four quarters. The balance sheet as of Dec'24 shows shareholder's funds of 438.87 million and total assets of 464.67 million.